文献速递慢性静脉疾病

Palmaz支架用于症状性下腔静脉重建的单中心回顾性经验

Inferior Vena Cava Reconstruction in Symptomatic Patients Using Palmaz Stents: A Retrospective Single-Center Experience.
PubMed 文献 · Ann Vasc Surg · 2020-02-04

该单中心回顾性研究纳入2002至2019年37例症状性慢性下腔静脉梗阻患者,使用68枚Palmaz球囊扩张支架行下腔静脉重建。

要点

  • Palmaz球囊扩张支架用于症状性下腔静脉重建技术可行,并发症率低。
  • 随访27例中19例(70%)维持原发通畅,6例需支架再扩张。
  • 恶性肿瘤相关梗阻的原发通畅时间较短(109天),非恶性病因较长(1.1年)。

核心结论

  • Palmaz球囊扩张支架用于症状性下腔静脉闭塞重建可行且有效,支架移位风险低。

研究设计与样本

  • 单中心回顾性研究,2002至2019年纳入37例症状性慢性下腔静脉梗阻患者(平均年龄51岁),共置入68枚Palmaz支架。

主要发现

  • 所有患者均成功恢复下腔静脉通畅,2/37(5.4%)出现并发症(支架内血栓形成、支架置入后8天移位)。
  • 随访27例中19/27(70%)维持原发通畅至末次随访(平均1.1年),6例成功行支架再扩张。
  • 原发辅助通畅(n=5)平均持续时间1.2年;晚期管腔丢失(n=13)在平均随访2.0年时为40%。
  • 恶性肿瘤所致闭塞的原发通畅时间为109天(范围1天至1.0年),其他病因所致闭塞为1.1年(范围2天至5.9年)。
  • Kaplan-Meier分析显示24和48个月原发通畅率为66%,原发辅助通畅率为84%。

临床怎么用

  • 对于症状性下腔静脉慢性闭塞,可考虑使用Palmaz球囊扩张支架进行重建。
  • 术后需影像随访监测支架通畅性,必要时行支架再扩张。

局限性

  • 回顾性单中心设计,样本量较小(37例),随访数据仅27例可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of stents for treating central venous occlusion is well described. Limited evidence exists related to Palmaz balloon-expandable stent use in inferior vena cava (IVC) reconstruction. We analyzed patency and complication rates after IVC reconstruction using Palmaz stents. METHODS: From 2002 to 2019, 37 patients (mean age: 51 year) underwent IVC reconstruction with 68 Palmaz stents. Indications were symptomatic chronic venous obstruction in the infrarenal (n = 25) and intrahepatic (n = 12) IVC. Demographic, operative, and imaging data were evaluated. Clinical data, abdominal CT, and/or duplex ultrasound were used to determine patency at follow-up. RESULTS: Restoration of caval patency was achieved in all patients, with complications in 2/37 (5.4%) patients (thrombus formation within the stent; stent embolization eight days after placement). Follow-up data were available for 27 patients. Primary patency was maintained through last follow-up in 19/27 (70%) patients (mean: 1.1 year), with successful stent redilation performed in 6 patients. Mean duration of primary-assisted patency (n = 5) was 1.2 year. Late lumen loss was (n = 13) was 40% during a mean time to follow-up of 2.0 years. Primary patency in patients with occlusion secondary to malignancy was 109 day (range: 1 day-1.0 year), whereas primary patency in patients with occlusion from other etiologies was 1.1 year (range: 2 day-5.9 year). The Kaplan-Meier analysis demonstrated primary and primary-assisted patency of 66% and 84%, respectively, at 24 and 48 months. CONCLUSIONS: Palmaz balloon-expandable stents for IVC reconstruction is feasible and effective for symptomatic IVC occlusion. Risk of stent migration was low.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Barrette LX, McLaughlin SW, Vance AZ, et al. Inferior Vena Cava Reconstruction in Symptomatic Patients Using Palmaz Stents: A Retrospective Single-Center Experience. Ann Vasc Surg. 2020. PMID: 32027985. doi:10.1016/j.avsg.2020.01.104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。